NOVEL AND EFFICIENT METHOD OF ANTICANCER DRUG DELIVERY

Information

  • Research Project
  • 2104393
  • ApplicationId
    2104393
  • Core Project Number
    R43CA062905
  • Full Project Number
    1R43CA062905-01A2
  • Serial Number
    62905
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/13/1995 - 29 years ago
  • Project End Date
    9/12/1995 - 28 years ago
  • Program Officer Name
  • Budget Start Date
    3/13/1995 - 29 years ago
  • Budget End Date
    9/12/1995 - 28 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    3/13/1995 - 29 years ago
Organizations

NOVEL AND EFFICIENT METHOD OF ANTICANCER DRUG DELIVERY

The contents of this proposal are based on the observation that, both in vitro and in vivo, the cytotoxicity of some anticancer drugs can be greatly increased if cells are transiently permeabilized, allowing easier passage of the drug, by application of short and intense pulsed electric fields. The objectives and specific aims of this current proposal are to extend the data we have already obtained on tumor regression in animal models with murine melanoma cell lines, by combining bleomycin with electric field. In particular, we will (i) compare different routes of administration, intratumor and intravenous, and investigate the effect of (ii) different dosages, and (iii) multiple treatments, all with bleomycin and optimized electrical parameters. Results of the combination therapy will be compared with three sets of control, namely, no drug and no electric field, and drug or electric field alone. Apart from usual monitoring and observation of the animals, detailed histopathological examinations will also be carried out. In addition, field plots with different geometry of the electrodes, caliper and needles, will be obtained. The long-term aim of the project is to treat human patients with skin cancers, particularly advanced melanoma and basal cell carcinoma by this novel method. PROPOSED COMMERCIAL APPLICATION: The technology will allow treatment of cancer patients using existing anticancer drugs with maximum efficacy. Electroporation-mediated chemotherapy has shown great promise in phase I/II clinical trial of patients with head and neck squamous cell carcinomas.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    GENETRONICS, INC.
  • Organization Department
  • Organization DUNS
    122735749
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211318
  • Organization District
    UNITED STATES